Oct 2 (Reuters) - Dimension Therapeutics Inc  DMTX.O  
    * Dimension board determines that Ultragenyx's unsolicited 
proposal to acquire dimension for $6.00 per share constitutes a 
"superior proposal" 
    * Dimension Therapeutics Inc - dimension board has not 
changed its recommendation in support of REGENXBIO transaction 
 
Source text for Eikon:  ID:nGNXOEPUKa  
Further company coverage:  DMTX.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))